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Abstract 
 
Information on human toxicokinetics plays an important role in the safety assessment of chemicals, even though there 
are few data requirements in the EU regulatory framework. While existing EU test methods and OECD test guidelines are 
mostly based on animal procedures, there are increasing opportunities to achieve a 3Rs impact in this area by exploiting 
modern developments. For example, whole-body toxicokinetic information can be obtained by using physiologically-based 
toxicokinetic (PBTK) models that integrate data generated by in vitro methods for absorption, distribution, metabolism 
and excretion (ADME). The development of an infrastructure providing access to such models and their underlying data 
needs to be accompanied by the establishment of standards for human in vitro ADME methods, the development of 
guidance on the development and application of such models and the creation of regulatory incentives. Taking these 
needs into account, this report describes the EURL ECVAM strategy to achieve a 3Rs impact in the area of toxicokinetics 
and systemic toxicity. The proposed activities are expected to lay the foundation for a risk assessment approach that is 
increasingly based on human data. Implementation of the strategy will rely on the coordinated efforts of multiple 
stakeholders. 
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Executive summary 
Information on the human toxicokinetics, or biological fate of a substance, plays an important role 
in human safety assessment. While there are few explicit requirements in EU chemicals legislation 
for the generation of human toxicokinetic data, such as human in vitro or in vivo measurements or 
computational predictions, the use of these data to support the assessment of systemic toxicity is 
widely recommended in regulatory guidance. For the generation of data, some EU test methods 
and OECD test guidelines are available, but these are mostly based on animal procedures, the 
traditional means of obtaining whole-body toxicokinetic parameters. Exploiting modern 
developments in predictive toxicology, there are increasing opportunities to generate human whole-
body toxicokinetic information by using physiologically-based toxicokinetic (PBTK) models. These 
models provide a means of integrating human data generated by in silico and in vitro methods for 
absorption, distribution, metabolism and excretion (ADME), the four underlying processes driving 
toxicokinetic behaviour. In general however, the lack of standardisation of these methods is 
hampering their regulatory acceptance and use. 
This report outlines the strategy proposed by the European Union Reference Laboratory for 
Alternatives to Animal Testing (EURL ECVAM) for achieving a 3Rs (replacement, reduction and 
refinement of animal experiments) impact in the area of toxicokinetics. The EURL ECVAM strategy 
identifies opportunities for generating and making better use of toxicokinetic data. Apart from 
specifying strategic aims and associated objectives to progress this field, the strategy is also 
intended to provide a framework for the identification and prioritisation of alternative test methods 
for ADME.  
Efforts in this area should be directed towards developing standards that will increase the 
development, harmonisation, validation and acceptance of human-relevant methods for ADME of 
substances, including nanomaterials. This will enable the generation of reliable data for 
toxicokinetic modelling in support of chemical safety assessment. Although ADME and 
toxicokinetics usually consider single substances, the information obtained may inform on risk 
assessment issues of mixtures and combined exposures as well. In parallel, in order to promote 
modelling efforts, an infrastructure needs to be established to make any human data, as well as 
existing animal data, readily available. To enhance the uptake of PBTK models, good modelling 
practice needs to be further developed and accepted at an international level. Finally, guidance is 
needed on how best to use human ADME and toxicokinetics data for decision making purposes. 
Regulatory anchoring might provide a boost in this respect. These efforts are expected to lay the 
foundation for a risk assessment approach that is increasingly based on human data, ultimately 
obviating the need for animal studies.  
The implementation of this strategy will rely not only on the efforts of EURL ECVAM, but on the 
collective and coordinated contribution of a wide range of stakeholders. 
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Glossary1  
 
3Rs replacement, reduction and refinement (of animal experiments) 
ADME  absorption, distribution, metabolism and excretion 
AUC area under (the plasma concentration-time) curve 
BPR EU Regulation on Biocidal Products (EU, 2012); Regulation (EU) No 528/2012 
CLP EU Regulation on Classification, Labelling and Packaging of substances and mixtures (EC, 2008); 
Regulation (EC) No 1272/2008 
Cmax maximum concentration (typically in plasma) following specified exposure/dose  
Css steady state concentration (typically in plasma) following specified exposure/dose 
CTK classical toxicokinetic (modelling) 
CPR EU Cosmetic Products Regulation (EC, 2009b); Regulation (EC) No 1223/2009 
DB-ALM EURL ECVAM DataBase service on ALternative Methods 
EC European Communities 
ECHA European Chemicals Agency 
EFSA European Food Safety Authority 
EURL ECVAM European Union Reference Laboratory for Alternatives to Animal Testing 
F fraction bioavailable unchanged (parent substance, i.e. non-metabolised) 
human based on a human in vitro method, a human in vivo measurement or on a prediction tool based on one of 
these data types (PBTK, QSAR) 
IATA integrated approaches to testing and assessment (to accommodate use of non-animal data) 
KinCalTool EURL ECVAM Kinetics Calculation Tool 
KinParDB EURL ECVAM Kinetic Parameters DataBase 
OECD  Organisation for Economic Co-operation and Development 
PBTK physiologically-based toxicokinetic (modelling) 
PPPR EU Regulations on Plant Protection Products (EC, 2009a; EU, 2013); Regulation (EC) No 1107/2009 and 
Commission Regulation (EU) No 283/2013 
QSAR quantitative structure-activity relationship 
REACH EU Regulation on Registration, Evaluation, Authorisation and restriction of CHemicals (EC, 2006); 
Regulation (EC) No 1907/2006 
SCCS European Commission Scientific Committee on Consumer Safety 
SEURAT-1 EC-FP7/Cosmetics Europe initiative on Safety Evaluation Ultimately Replacing Animal Testing - 
Towards the Replacement of in vivo Repeated Dose Systemic Toxicity Testing 
TG test guideline 
TK toxicokinetics – describes and models the time-dependent fate of a substance within the body in 
dependence of its ADME (rate and extent); synonymous to pharmacokinetics or PK 
t1/2 blood/plasma half-life 
tmax time to maximum concentration (typically in plasma) following specified exposure/dose  
TWI Tolerable Weekly Intake 
 
  
                                                        
1 Coloured terms are clickable for direct internet links 
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1 – Introduction 
Toxicokinetics (TK) describes the concentration and time-dependent fate of a substance within an 
organism whereas toxicodynamics describes the subsequent interaction with biological targets and 
how this may lead to adverse health effects. The time-course of the internal or systemic exposure 
is the combined outcome of four underlying processes: absorption, distribution, metabolism and 
excretion (ADME). Although they are strongly linked, it is important to distinguish between ADME 
and TK. In vitro methods can provide data on individual ADME parameters, but do not directly 
generate whole-body (animal or human) TK parameters such as the maximum concentration 
reached in blood/plasma. Traditionally, TK parameters have been obtained from in vivo 
experiments, but there are increasing opportunities to derive this information by physiologically-
based toxicokinetic (PBTK) modelling (Figure 1). PBTK models provide a means of simulating TK 
profiles by integrating (chemical-independent) physiological and anatomical information with 
(chemical-dependent) ADME parameters. The latter can be generated by quantitative structure-
activity relationship (QSAR) models and in vitro methods. PBTK models are increasingly being used 
in the chemical risk assessment process to take into account relevant in vivo differences (cross-
species, cross-route and inter-individual) and to make better use of in vitro toxicity results.  
 
Figure 1: Physiologically-based toxicokinetic (PBTK) modelling integrating ADME parameters 
derived from in silico and in vitro methods to simulate the concentration-time course of a 
substance in vivo. 
 
There are very few legal requirements in the EU chemicals legislation for the generation of human 
ADME and TK data and the requirements for ADME and TK data are not consistent (Table 1). 
However, the use of ADME/TK data when available to support the assessment of systemic toxicity 
is highly recommended in regulatory guidance and scientific opinions (Table 2). For the generation 
of new data, only three ADME/TK test methods are available in the EU test methods regulation 
(EU, 2012) and in the OECD (Organisation for Economic Co-operation and Development) guidelines 
for the testing of chemicals. With the exception of OECD TG 428 for in vitro dermal absorption, 
guideline methods such as OECD TGs 417 and 427 are based on animal tests (OECD, 2004a; OECD, 
2004b; OECD, 2010). OECD TG 417 studies typically provide rather isolated species-, dose-, and 
route-specific (mostly oral) data on absorption, tissue distribution or metabolism. In rare cases, 
OECD TG 417 is used to give the integrated TK profile of a substance, i.e. the concentration-time 
course of the parent compound and its metabolites. Although many in silico and in vitro methods 
with varying stages of maturity are available and used for integrated PBTK modelling to predict the 
concentration-time course, these methods are not generally sufficiently standardised (Bessems et 
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al., 2014) and scrutinised for relevance and reliability which is hampering their regulatory 
acceptance and widespread use. 
The need for human TK information on one hand, combined with the paucity of legal requirements 
for animal TK data on the other, provides an opportunity to develop a risk assessment approach 
that is increasingly based on human ADME and TK data. A fundamental transition is needed in the 
toxicological testing and risk assessment methodology away from the widely used default 
approach using external animal dose levels and external human exposures. At best this only 
accommodates the use of species- and route-specific information on absorption, instead of taking 
the systemic exposure (AUC, Cmax etc.) into account. A scientifically more advanced and 
toxicologically relevant approach based on internal concentrations is highly recommended. In 
addition to regulatory drivers (e.g. EU ban on animal testing of cosmetic ingredients), such a 
transition is motivated by scientific considerations. Animals are often poor models for humans due 
to sometimes well-known qualitative and also quantitative differences in their physiology and 
metabolism (Coecke et al., 2005; Pelkonen et al., 2009; Greek and Menache, 2013; Coecke et al, 
2014). In order to use human in vitro toxicity data for human risk assessment, a stronger focus on 
internal exposure (e.g. AUC and Cmax of the putative toxicant) is warranted. In this approach, in vitro 
free (unbound to protein) concentrations (points of departure) would be compared to simulated or 
measured (e.g. by biomonitoring) human in vivo systemic exposure free concentrations. The 
resulting margin of internal exposure would then be used to characterise the risk (Bessems et al., 
manuscript in preparation).  
Until a full replacement of animal testing for systemic toxicity is reached, a more intelligent and 
systematic generation and use of ADME/TK information will provide a means of reduction and 
refinement. For example, the reliable prediction of extremely low absorption could support the 
waiving of animal toxicity test requirements based on the low internal exposure expected. The 
prediction and the measuring of internal exposure can also support dose range finding, e.g. 
avoiding irrelevant high-dose testing if high doses are predicted to result in kinetic non-linearity. 
Measuring systemic exposure across dose levels, sexes, study durations, species, strains and life 
stages in ongoing animal toxicity studies, i.e. without using satellite animals (preferably using 
microsampling), will significantly reduce uncertainties involved in various extrapolations needed in 
the risk characterisation phase (Bessems and Geraets, 2013; Terry et al., 2014). Moreover, it may 
reduce the chance that the results of one animal study will unnecessarily trigger another. This 
could happen for example when non-linearity of the dose-response is caused by non-linearity of 
the internal exposure. Lastly, ADME properties form an important source of information in 
integrated approaches to testing and assessment (IATA) that are designed to optimally exploit 
various streams of non-animal data (OECD, 2015). 
The purpose of this document is to present the EURL ECVAM strategy to avoid, reduce and refine 
animal testing in the assessment of toxicokinetics and systemic toxicity of substances. This 
strategy is also applicable to nanomaterials, although specific technical provisions are needed in 
places due to their particular physicochemical properties. The intention was to focus on pragmatic 
options that could be expected to have a significant short to mid-term 3Rs impact, while at the 
same time laying the foundation for a risk assessment approach that is increasingly based on 
human ADME/TK data. The implementation of this strategy will rely not only on the efforts of EURL 
ECVAM, but on the collective and coordinated contribution of a wide range of stakeholders. 
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2 – Regulatory provisions on ADME and TK 
Within EU regulatory frameworks, route-to-route extrapolation is probably the most important use-
case for information on species- and route-specific ADME and, if available, systemic exposure 
(whole-body TK). However, such information is not consistently required. Table 1 provides an 
overview of data requirements and recommendations under the frameworks that are most relevant 
in this respect, i.e. CLP (classification and labelling), REACH (industrial chemicals), CPR (cosmetics), 
BPR (biocides) and PPPR (pesticides). It is noted that over time, legislative frameworks have placed 
increasing emphasis on the use of systemic exposure information for human risk assessment 
purposes. Except for the CPR however, these needs are being addressed for the most part using 
animal data. 
 
Table 1: Requirements and recommendations for ADME/TK information2 in EU legal frameworks3.  
Regulation 
Required or 
recommended 
What ADME and/or TK 
parameter? 
Use 
CLP  
Regulation (EC) 
No 1272/2008 
Not required 
but use if 
available  
Non-specific but numerous 
examples about use of species- 
and route-specific TK 
information 
Shall and/or should be used as weight of 
evidence to classify, lower the classification 
or abstain from classification for a particular 
toxicodynamic endpoint. 
REACH  
Regulation (EC) 
No 1907/2006 
Not required 
but use if 
available 
TK (A, D, M, E) 
In REACH Guidance documents, many 
examples of recommendations that would 
replace default assessment factors (e.g. 
Sections R.7.12 and R.8.4 in Chapters R.7.C 
and R.8, respectively). 
CPR 
Regulation (EC) 
No 1223/2009 
Recommended 
by SCCS (2012) 
Human systemic exposure 
Human dermal absorption 
Biotransformation 
Route-to-route extrapolation 
BPR 
Regulation (EU) 
No 528/2012 
Required 
A: rate and extent 
D: tissue 
M: pathway + degree 
E: routes and rate 
When accumulation indicated, 90 d study 
preferred over 28 d. 
If no significant human exposure and no 
systemic absorption F = 0, reproduction 
toxicity study not needed. 
PPPR 
Regulation (EC) 
No 1107/2009  
Commission 
Regulation (EU) 
No 283/2013 
Required 
Oral A, D, M, E 
Oral F, AUC, Cmax, Tmax 
Bioaccumulation potential, t1/2 
Often dermal A (in vitro human), 
D, M, E and F 
Sometimes inhalation A 
In vitro comparative metabolism 
TK short-term toxicity studies 
Study design (e.g. dose selection) 
Interspecies extrapolation 
Route-to-route extrapolation 
Residue definition (testing of metabolites) 
 
                                                        
2
 Except when stated otherwise, in this table all ADME and TK parameters refer to animal ADME and TK. 
3
 See glossary for full titles of the regulations and explanation of the toxicokinetic terms, including A, D, M, E. 
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In addition to the legal requirements, more detailed recommendations are laid down in various 
guidance documents, developed for example by the EU Member States (e.g. REACH Guidance) or by 
Scientific Committees (e.g. Notes of Guidance: SCCS, 2012). Table 2 provides examples of how the 
required and/or recommended ADME/TK information can be used in regulatory decision making in 
the EU.  
 
Table 2: Use cases for ADME and TK information suggested by various EU guidance.  
Use cases Examples Source 
Waiving4 
specific in vivo 
study 
Reproductive study if no systemic absorption. 
Dermal acute toxicity if no dermal absorption.  
BPR 
 
If somatic genotoxicant and germ cells reached, then in vivo 
germ cell genotoxicity can be skipped. 
EURL ECVAM Strategy Genotoxicity 
(Corvi, 2013), EURL ECVAM Strategy 
Acute systemic toxicity (Prieto, 2014) 
If substance accumulates, skip 28 d study and do 90 d. 
Inclusion blood sampling one study may avoid another. 
REACH, BPR, PPPR 
Read across Toxicokinetic studies, kinetic and metabolic factors.  
ECHA report alternatives (ECHA, 
2014) 
IATA 
ADME and TK models are regarded to be basic elements.  
ECHA report alternatives (ECHA, 
2014), OECD WS Report (OECD, 
2015) 
Skin bioavailability critical event in adverse outcome 
pathway skin sensitisation. 
EURL ECVAM Strategy Skin 
sensitisation (Casati, 2013) 
Metabolic stability/clearance + metabolite identification in 
vitro. Possibly preventing in vivo acute systemic tox. testing. 
EURL ECVAM Strategy Acute 
systemic toxicity (Prieto, 2014) 
In vivo study 
design 
Designing (further) toxicity studies (e.g. species selection 
based on in vitro metabolism species comparison) and to 
help their interpretation. 
SCCS (2012) Notes of Guidance,  
REACH Guidance on TK, R.12, 
Commission Regulation (EU) No 
283/2013 
Risk 
assessment 
extrapolations 
Use of chemical-specific data on ADME and/or TK instead of 
default Assessment Factors. 
PPPR,  
SCCS (2012) Notes of Guidance 
 TK + human urinary data to set the TWI for cadmium EFSA (2009) 
 
PBTK to reduce extrapolation uncertainty and for derivation 
of AOELs5. Quantitative use of human in vitro ADME data. 
EFSA PPR Opinion, 2006 
Risk 
management 
Persistency and bioaccumulation noted as selection criterion 
for the emerging chemical risk framework. 
EFSA (2014),  
EURL ECVAM Strategy fish acute 
toxicity + bioaccumulation (Halder, 
2014) 
Establishment of ‘common assessment groups’ using 
human metabolism (in silico, in vitro, in vivo) in public 
health issue of exposure to mixtures. 
EFSA, 2014 
                                                        
4
 Waiving an information need (animal study): based on arguments, not deemed necessary to carry out the study. 
5
 Acceptable Operator Exposure Levels as required by Regulation (EC) No 1107/2009 (PPPR). 
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Comparisons between human and animal ADME/TK data (in silico, in vitro or preferably in vivo 
when available) can lead to an overall reduction of animal testing by increasing the relevance of 
animal toxicity studies, where these are required. This is achieved by identifying and avoiding 
animal species with ADME/TK for the substance that is very different from human ADME/TK. This 
could be based on comparison of any relevant parameter or process, e.g. most relevant 
metabolite(s), rate of formation of a likely toxic metabolite, and allometric scalability of various 
kinetic parameters such as hepatic metabolic clearance, renal clearance or plasma half-life 
(Bessems and Geraets, 2013). In addition, risk assessment is served best when more human 
ADME/TK data is available. The EFSA PPR panel noted for example already in 2006 that human 
ADME/TK data reduce the uncertainty related to the extrapolation process from animal 
toxicodynamics data both in terms of species and dose, and help in assessing the relevance for 
humans of findings in animals (EFSA, 2006).  
There are international developments as well. OECD Guidance Document 116 on chronic and 
carcinogenicity test guidelines (OECD, 2012) attributes significant value to information on ADME 
for improving the study design. The information helps to select the highest relevant dose level in 
order to prevent non-linear kinetics from occurring, thus enabling refinement through study design. 
OECD Guidance Document 151 supports the extended one generation reproductive toxicity test 
guideline (OECD, 2013). It states that “ADME studies should be undertaken to facilitate 
extrapolation from the oral to the dermal route, if this is required”. Furthermore, ADME received 
attention at a recent OECD workshop as being an important element of IATA (OECD, 2015). 
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3 – Strategy to replace, reduce and refine the use of animals for human TK 
Although the value of human ADME and TK data in establishing health risks of substances is widely 
acknowledged, concrete guidance and case studies on how to generate the in vitro ADME and in 
silico TK parameters and how to use this information in different decision making contexts and 
within IATA is largely missing. Some human in vitro methods to measure an ADME property exist, 
such as for absorption via the gastrointestinal tract or for hepatic metabolic clearance, albeit with 
uncertainties regarding their applicability domain. In other cases, such as renal excretion, further 
efforts are needed to develop suitable methods (Mostrag-Szlichtyng and Worth, 2010; Adler et al., 
2011; Bessems et al., 2014; EFSA, 2014). In most cases however, the available methods are not 
standardised. This is an impediment to their use and acceptance. Therefore, in addition to the 
development of new methods, there is a need to characterise existing methods in a systematic 
manner (Adler et al., 2011; Bessems et al., 2014; EFSA, 2014). 
With a view to replacing, reducing and refining animal testing in the assessment of toxicokinetics 
and systemic toxicity, EURL ECVAM has defined four strategic aims (Figure 2).  
1. ADME methods: Development and standardisation of human in vitro ADME methods. 
2. Kinetic modelling: Portals and good kinetic modelling practice. 
3. Data collection: Analytics and databases to serve kinetic modelling.  
4. Regulatory anchoring: Legislation and guidance on human ADME/TK data. 
The first three are intended to enhance the availability and usefulness of the necessary tools while 
the fourth is intended to foster a regulatory evolution towards stronger requirements for ADME and 
TK information based on non-animal and human-relevant approaches. In the following paragraphs, 
the four strategic aims are further explained and translated into concrete objectives.  
 
Figure 2: Four strategic aims to facilitate generation and use of human ADME and TK data. 
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3.1 Strategic aim 1: Development and standardisation of human ADME methods 
In order to promote the acceptance of non-animal ADME/TK data for regulatory purposes, an 
international quality assurance framework needs to be established (SCHER, 2013; Coecke et al. 
2014). This framework should be applicable to ADME data generated by in vitro test methods and 
QSARs, TK data generated by integrated PBTK models, as well as human in vivo data obtained in 
monitoring programs or volunteer studies (SCHER, 2013).  
Some elements of this framework are already established or under development. For example, the 
QSAR Model Reporting Format (QMRF) and QSAR Prediction Reporting Format (QPRF) are 
internationally recognised standards for reporting the characteristics of QSAR models, and the 
quality of QSAR predictions, respectively6. More recently, the OECD has published a guidance 
document on how to characterise and describe non-guideline in vitro test methods (OECD, 2014). 
Guidance on the characterisation, documentation and application of PBTK models has been 
published by the World Health Organisation (WHO/IPCS, 2010). 
Other elements of this framework need to be developed. In particular, standards for in vitro ADME 
methods will provide a means of characterising and comparing in vitro methods which typically 
provide the same kind of information (ADME property) but which may differ considerably in terms 
of the underlying test systems and experimental protocols used. Different domains (varying 
physicochemical properties, magnitude of output parameter) may require different standards.  
Lastly and as mentioned earlier, for several ADME endpoints, test methods need to be developed, 
improved or their applicability domain widened. 
 
Objective 1.1 – Development of standards for human in vitro ADME methods  
In order to make better use of human in vitro methods for ADME properties, there is a need to 
develop a framework aiming to (a) describe a method including the characteristics of the test 
system and the results of the test method in an objective and standardised way, (b) to assess the 
performance of the method (reliability and relevance) and (c) to define its applicability in terms of 
the ranges of physicochemical properties of substances, its measurement outputs and the time-
scales for which the test system is valid. 
Furthermore, the OECD reporting standard for non-guideline in vitro methods (OECD, 2014) needs 
to be evaluated for its applicability to ADME methods. Additional standards may need to be 
established to characterise and compare different methods within a given class of methods (that 
generate the same ADME parameter). A few other important issues need to be taken into 
consideration here. One issue is the fact that not all ADME methods are necessarily designed to be 
directly predictive of an in vivo parameter as such. This means that the classical validation based 
on a direct comparison of a human in vitro ADME method data against human in vivo data is not 
meaningful7. Prediction methods as complex as PBTK models would be needed to interpret the 
human in vitro ADME data. Nevertheless, simple ADME parameters obtained using standardised 
                                                        
6
 JRC QSAR Model Database and QSAR Model Reporting Formats. https://eurl-ecvam.jrc.ec.europa.eu/databases/jrc-qsar-
model-database-and-qsar-model-reporting-formats. 
7
 In this context, this could mean total in vivo absorption (relative to the applied dose) measured over 7 days. Whereas an 
in vitro absorption method may deliver a flux, being an absorption rate per unit area (e.g. μmol min
-1
 cm
2
). 
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human in vitro methods could be used directly such as for priority setting and ranking (rates of 
absorption) as well as in the context of IATA. 
 
Objective 1.2 – Human route-specific absorption methodology  
For in vitro dermal absorption, an OECD TG does exist (TG 428). However, this TG needs critical 
review and/or revision as the current method is focussed mainly on determining the relative 
amount of substance systemically absorbed and much less so on establishing dermal flux values 
(through the skin) and the underlying determinants such as dermal diffusion coefficients that may 
be needed for PBTK modelling (Bessems et al., 2014). EFSA has published opinions on the 
adaptation and improvement of this TG, especially in relation to the interpretation and standardised 
reporting of results of OECD TG 428 (EFSA, 2011; EFSA, 2012). For other routes, OECD TGs and 
validated test methods are lacking.  
It is important to improve and/or standardise a set of representative in vitro methods that can be 
used to derive harmonised standards for this class of test methods (which measure the 
permeability of external membranes). This is relevant to methods for assessing exposure via skin 
as well as by inhalation or ingestion. Although this formally applies to tissue distribution, a further 
step will be to improve and develop equivalent test methods and standards for in vitro methods 
that measure the passive permeability of internal membranes, such as the blood-brain barrier and 
the placental barrier. Obviously, in the end the same applies to active transport across barriers. 
 
Objective 1.3 – Human tissue distribution and protein binding methodology  
Several in vitro test methods that measure parameters that drive the distribution (partitioning 
coefficients, protein binding), including an indication of their level of development, are described 
elsewhere (Bessems et al., 2014). Distribution is a key driver of phenomena like persistency. For 
example, high fat solubility increases the risk of persistency and bioaccumulation.  
A set of standards to improve the quality and traceability of PBTK input parameters such as 
partitioning coefficients and protein binding is crucial. Improvements and widening of applicability 
domains may be needed as well.  
 
Objective 1.4 – Human metabolic stability/clearance methodology 
Human metabolic clearance levels (or their absence, defined as metabolic stability) in liver, skin 
and lungs being the most relevant portals of entry, are important determinants of bioavailability as 
well as the (pre-systemic) elimination of substances from the body. These are essential pieces of 
information for PBTK modelling. Metabolic clearance might even be the most influential parameter 
that determines terminal elimination half-life (and thus persistency and risk for human 
bioaccumulation), systemic toxicity upon dermal exposure, as well as inter-individual variability in 
plasma levels. Harmonised standards are needed since the methods submitted to EURL ECVAM and 
available in the scientific literature vary considerably. For example, there are differences in the 
in vitro test system (e.g. subcellular fraction, primary cells, cell lines, liver slices) and the ability to 
deal with fast or slowly cleared compounds (Brandon et al., 2003; Di and Obach, 2015).  
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Objective 1.5 – Human xenobiotic metabolic pathway profiling methodology 
The identification of the main and most relevant human metabolites serves multiple applications. 
For example, the identification of common metabolites for two substances in a mixture might 
trigger the assessment to be based on the properties of the common active metabolite. As a 
multitude of methods is used under various performance requirements, a set of standards needs to 
be developed for this class of methods. Induction and inhibition of biotransformation enzymes are 
important process as well. Induction is currently the subject of a draft OECD TG. 
 
Objective 1.6 – Human route-specific excretion methodology 
Urinary and biliary excretion pathways are the two most relevant excretion pathways. To our 
knowledge, there are no in vitro methods available at the moment for urinary excretion because of 
the complex renal mechanism of formation of primary urine, passive and active reuptake and the 
dependence of these mechanisms on differences in pressure and osmolarity between blood and 
primary urine. For biliary clearance, some in vitro methods have been reported (De Bruyn et al., 
2013), but further development and standardisation work is necessary to identify representative 
methods based on which harmonised standards can be established. Although passive excretion has 
been suggested to suffice for ‘Tier 1 PBTK modelling’, it is clear that in the future, excretion based 
on active transporters needs to be taken into account as well. 
 
 
3.2 Strategic aim 2: Kinetic modelling  
In order to facilitate the use of PBTK modelling in the risk assessment process, there is a need to 
make in silico ADME prediction tools as well as PBTK modelling tools readily accessible and easy to 
apply, and to establish good practice in kinetic modelling (WHO/IPCS, 2010).  
 
Objective 2.1 – Comprehensive web-based kinetic modelling portals  
Kinetic modelling includes classical kinetic modelling approaches, PBTK modelling, and also in silico 
prediction of ADME parameters. It is generally felt to be quite a complex process that requires 
experts in TK, mathematical modellers and regulatory risk assessors to work together (WHO/IPCS, 
2010; Bessems et al., 2014). The establishment of comprehensive 'one-stop' web-based kinetic 
modelling portals is needed to provide a collaborative environment to facilitate the development 
and use of kinetic models. Such portals should contain or link to freely available kinetic modelling 
tools and databases (objective 3.2).  
 
Objective 2.2 – Good kinetic modelling practice 
To facilitate the regulatory acceptance of PBTK models, good practice needs to be established for 
the development and documentation of models based on already available guidance (WHO/IPCS, 
2010). It is necessary to develop standard reporting formats, equivalent in purpose to the QSAR 
Model Reporting Format (QMRF) and QSAR Prediction Reporting Format (QPRF), for presenting 
sufficient details of model construct and application. These reporting formats should include 
assumptions made concerning the mode of action, the most relevant qualitative dose metric 
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(parent or metabolite), the most relevant quantitative dose metric (AUC, Cmax, rate of formation) 
and address uncertainty issues (see also 3.4). This will help kinetic model developers to take into 
account all the necessary considerations and facilitate uptake of kinetic modelling approaches in 
decision making.  
The formation of a PBTK modelling expert group, ideally by an international organisation, would be 
an appropriate means of developing good PBTK modelling practice.  
 
 
3.3 Strategic aim 3: Data collection - Generation and storage of ADME and TK data 
To support objectives 1 and 2, a concerted action to stimulate generation and collection of data is 
needed. These data should ideally be quality-assured and stored in readily accessible (and 
preferably free-to-use) databases in order to make the process of establishing human ADME and 
TK parameters as transparent and efficient as possible (Bessems et al., 2014). Sharing of 
proprietary data could enable the generation of a large, high quality database of ‘paired’ in vitro 
and in vivo human data on the same substance. This could be used to investigate the predictive 
value of in vitro data (Leist et al., 2014). Databases are a necessary building block for ready to use 
PBTK modelling and should become an important part of comprehensive web-based PBTK 
modelling platforms (see objective 2.1). 
 
Objective 3.1 – Collection of human in vitro ADME and in vivo TK information 
There is considerable need for standardised in vitro generation of ADME parameters. Ideally, these 
ADME parameters should be stored in open-access curated databases. This would speed up the 
development of in silico (QSAR) ADME prediction tools as well as the parameterisation of PBTK 
models. 
Simultaneous measurements of external exposure and systemic exposure in order to establish real-
life human TK are scarce. A concerted effort is necessary to collect and store in vivo human ADME 
and TK information by building on human exposure monitoring programmes (e.g. dietary intake 
studies, occupational monitoring) as well as on human biomonitoring programmes (e.g. 
measurements in biofluids). If doubts remain and more specific human in vivo benchmarking is 
required, controlled human microdosing in volunteer studies could be performed with the use of 
specific isotope labelling (Madeen et al., 2015). 
 
Objective 3.2 – Databases  
In order to facilitate human PBTK modelling, centralised publicly available (web-based) databases 
facilities containing the following are crucial:  
 A collection of human ADME data obtained by in vitro measurements.  
 Anatomical and physiological data including their variation in the human population. An 
example is the RIVM Interspecies database (http://www.interspeciesinfo.com); 
 In vivo human TK information. An example is the EURL ECVAM KinParDB (https://eurl-
ecvam.jrc.ec.europa.eu/validation-regulatory-acceptance/toxicokinetics). 
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Sparse but relevant kinetic data may already be available in various databases from the JRC and 
others that were not specifically designed for storage of ADME data, such as DB-ALM, the 
DataBaseservice on ALternative Methods (http://ecvam-dbalm.jrc.ec.europa.eu), the QSAR Model 
Database (http://ihcp.jrc.ec.europa.eu/our_databases/jrc-qsar-inventory) and databases that 
participate in the OECD eChemPortal  
(http://www.echemportal.org/echemportal/propertysearch/page.action?pageID=0). 
 
Objective 3.3 – Sampling strategies, methods, preparations and analytical determination 
Sampling strategies, sampling methods, sample pre-treatment and final analytical determination 
and quantification are all necessary for the transition to a human-based IATA. This pertains to in 
vitro ADME testing (Broeders et al., 2012) and to the collection of human in vivo data on TK 
(biomonitoring and human volunteer studies). This also concerns in vitro toxicity testing where the 
in vitro kinetics should be measured, i.e. the concentration-time profile of the chemical and/or 
metabolites intracellular as well as in the incubation medium (Blaauboer, 2010; Wilmes et al., 
2013). And it pertains as well to animal toxicity testing as long as it is still performed in order to 
improve study design and value for risk assessment (Creton et al., 2012). The issue was identified 
previously as a high priority (Bessems et al., 2014), i.e. ‘high-throughput and low cost analytical 
facilities to measure chemicals in physiological media’. 
 
 
3.4 Strategic aim 4: Regulatory anchoring of human ADME and TK  
The inherent value of human ADME and TK information in risk assessment is obvious, be it based 
on in silico, in vitro and/or in vivo approaches. However, it is not always obvious which particular 
ADME parameter (e.g. relative absorption or absorption rate), or which TK parameter (e.g. AUC or 
Cmax) is needed for a particular decision. Clarity is often lacking too regarding if and how human 
variability should be taken into consideration and what level of uncertainty is tolerable for various 
ADME/TK information elements. 
 
Objective 4.1 – Guidance on the use of human ADME and TK data in IATA 
Reliable information on human ADME parameter values is helpful in the development and 
application of IATA. For example, extremely low absorption rates could justify the waiving of certain 
animal bioassays (analytical precision becomes very important here, see objective 3.3), local (skin) 
bioavailability is a key consideration for assessing skin sensitisation, and low whole body clearance, 
indicated by low urinary excretion and/or high metabolic stability, indicates human persistency of a 
substance. Further guidance is therefore needed on the use of ADME/TK data in IATA for specific 
endpoints, including how to characterise the uncertainty in conclusions drawn from these data. 
Uncertainty may result, for example, from the reliability and relevance of the underlying ADME/TK 
methods. 
 
15 
 
Objective 4.2 – Evolution of legislative anchoring of human ADME and TK information 
There is growing awareness that human-relevant ADME and TK data are instrumental for a much 
stronger role of non-animal approaches in regulatory risk assessment. This implies a transition 
from the current animal-based testing paradigm to one that is based on 21st century science with 
greater reliance on human-relevant in vitro testing and human in vivo data (US NAS, 2007; SCHER, 
2013; US EPA, 2014). In order to achieve this, there is a need for a stronger regulatory anchoring of 
human in silico and in vitro ADME data, of human PBTK modelling tools to integrate human ADME 
data as well as of collecting human in vivo data where possible to support this. 
 
 
3.5 Timelines 
In Figure 3, an overview is presented of the strategic aims and related objectives with indicative 
timelines for meeting the objectives. This assumes optimal conditions in terms of the availability of 
necessary expertise and resources.  
 
Figure 3: Indicative timelines for critical developments in the human ADME and TK areas. 
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4 – Conclusions 
This document presents EURL ECVAM's strategic view on how to achieve a significant 3Rs impact in 
the assessment of toxicokinetics and systemic toxicity. Grouped under four strategic aims, a 
number of objectives and related activities have been identified to foster the generation and more 
intelligent use of human toxicokinetic data. In particular, the development of standards and a 
quality assurance framework to support the acceptance of human ADME/TK methods, and the 
targeted generation of relevant in silico and in vitro toxicokinetic data and their integration via 
PBTK modelling is expected to have a significant impact on the 3Rs. These activities will also lay 
the foundation for a more human-relevant approach to the safety assessment of chemicals. This 
strategy document is also intended to provide a framework for the prioritisation of alternative test 
methods for validation by EURL ECVAM towards regulatory acceptance and use.   
EURL ECVAM has already taken some important steps consistent with these strategic aims. For 
example, a pilot project delivered a kinetic parameters database (KinParDB) as well as a user-
friendly kinetic modelling tool (KinCalTool). More recently, EURL ECVAM has started to explore the 
development of standards for human in vitro hepatic metabolic clearance methods. Furthermore, 
with a view to developing a risk assessment approach based entirely on non-animal methods, EURL 
ECVAM has been working closely with other partners within the SEURAT-1 initiative to explore the 
use of in silico models in performing route-to-route extrapolations and in vitro-to-in vivo 
comparisons. 
The strategy outlined here is intended to be inclusive. EURL ECVAM has an important role to play in 
its implementation, but achievement of the objectives will depend on the proactive and coordinated 
engagement of multiple stakeholders. EURL ECVAM will continue to review its work programme in 
the light of developments in this field and with a view to providing added value at the EU and 
international levels.  
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